Japan· JP-3999043F2026
バリシチニブ
A baricitinib product containing バリシチニブ, registered in Japan by 日本イーライリリー, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Baricitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF02 (baricitinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Baricitinib · ATC L04AF02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of baricitinib costs, country by country.
Normalised to the WHO defined daily dose (3 mg), the median price runs from $26.41 in France to $138.66 in United States — a ×5.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Baricitinib · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- US United States$138.66 (acquisition cost)
- CH Switzerland$62.27
- FR France$26.41
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- バリシチニブ
- Manufacturer
- 日本イーライリリー
- Country
- Japan (JP)
- ATC code
- L04AF02
- ATC class
- Baricitinib
- Defined daily dose
- 3 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
368 interactions on record for baricitinib.
Graded by severity as the source publishes them — 295 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Baricitinib · interactions on record
368 records
- 295 severe
- 67 moderate
- 6 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AF02
Baricitinib, as other registers publish it.
- United StatesBaricitinibEli Lilly and Company
- United KingdomBaricitinib 2mg tabletsEli Lilly and Company Ltd
- United KingdomBaricitinib 2mg tabletsA A H Pharmaceuticals Ltd
- United KingdomBaricitinib 4mg tabletsA A H Pharmaceuticals Ltd
- United KingdomBaricitinib 4mg tabletsEli Lilly and Company Ltd
- FinlandOlumiantEli Lilly Nederland B.V.
- United StatesOlumiantEli Lilly and Company
- United StatesOlumiantEli Lilly and Company
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6e92dd0-c4cc-49af-990e-e1e5b3dd1534 GET /v1/drugs/c6e92dd0-c4cc-49af-990e-e1e5b3dd1534?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999043F2026",
"category": "内用薬",
"price_yen": 4820,
"generic_name": "バリシチニブ",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about baricitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.